MAP2K2 (MEK2) is a dual-specificity kinase that functions as a critical component of the MAPK signaling cascade by catalyzing the concomitant phosphorylation of threonine and tyrosine residues in ERK1 and ERK2 MAP kinases 1. The gene is located on chromosome 19 and plays essential roles in cell growth, differentiation, and survival signaling 1. MAP2K2 activates the ERK pathway, which is frequently dysregulated in cancer, making it an important therapeutic target 2. In colorectal cancer, the RAS/RAF/MEK/ERK pathway involving MAP2K2 can be suppressed by certain ribosomal proteins 3. Clinical studies demonstrate that MEK1/2 inhibitors targeting MAP2K2 show significant efficacy across various cancer types, including histiocytic neoplasms with an 89% overall response rate 4 and BRAF-mutated tumors with a 38% response rate 5. In multiple myeloma, MAP2K2 promotes cell proliferation through the YTHDF2/STAT5A/MAP2K2/p-ERK signaling axis 6. Additionally, MAP2K2 contributes to resistance against VEGFR inhibitors in renal cell carcinoma through a positive feedback loop with transcription factor SP1 2. These findings establish MAP2K2 as both a key oncogenic driver and a validated therapeutic target across multiple cancer types.